secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABBOTT LABORATORIES (ABT)
CIK:        0000001800
Form:       8-K
Filed at:   2025-01-22T23:59:59+00:00
Accession:  0001628280-25-002092
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Abbott Q4 organic base business sales +10.1%; FY2025 adj. EPS guidance $5.05-$5.25
--------------------------------------------------------------------------------

- Q4 reported sales $11.0B (+7.2% YoY); organic base business (ex-COVID) grew 10.1%.
- Q4 GAAP diluted EPS $5.27; adjusted diluted EPS $1.34 (core measure).
- Full-year 2024 sales $42.0B (+4.6% reported); organic base business +9.6%; adjusted EPS $4.67.
- Medical Devices Q4 sales $5.05B (+13.7% reported); Diabetes Care FreeStyle Libre grew 22.7% to $1.86B.
- FY2025 guidance: organic sales growth 7.5%-8.5%; adjusted EPS $5.05-$5.25; op. margin 23.5%-24.0%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/0001628280-25-002092-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1800/000162828025002092/abt-20250122.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-002092

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer